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Introduction: Thymoma is a rare tumor for which there is little
randomized evidence to guide treatment. Because of the lack of
high-quality evidence, a formal consensus-based approach was used
to develop recommendations on treatment.
Methods: A systematic refview of the literature was performed.
Recommendations were formed from available evidence and devel-
oped through a two-round modified Delphi consensus approach.
Results: The treatment recommendations are summarized as fol-
lows: Stage I—complete resection of the entire thymus without
neoadjuvant or adjuvant therapy. Stage II—complete resection of
the entire thymus with consideration of adjuvant radiation for
high-risk tumors. Stage IIIA—surgery either initially or after neo-
adjuvant therapy, or surgery followed by adjuvant therapy. Stage
IIIB—treatment may include a combination of chemotherapy, radi-
ation, and/or surgery, or if technically possible, surgery in combi-
nation with chemoradiotherapy (concurrent cisplatin based). For
bulky tumors, consideration should be given to sequential chemo-
therapy followed by radiation. Stage IVA—as per stage III, with
surgery only if metastases can be resected. Stage IVB—treatment on
an individual case basis (no generic recommendations). Recurrent
disease—consider surgery, radiation, and/or chemoradiation. Che-
moradiation should be considered in all medically inoperable and
technically inoperable patients.
Conclusion: Consensus was achieved on these recommendations,
which serve to provide practical guidance to the physician treating
this rare disease.
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Thymoma is a neoplasm of the thymus that originates in thegland’s epithelial tissue. The incidence of thymoma in the
United States is approximately 0.15 per 100,000 person-
years.1 Thymomas are typically slow-growing tumors that
spread by local extension. Metastases are usually confined to
the pleura, pericardium, or diaphragm, whereas extrathoracic
metastases are uncommon.2,3 Thymomas have a tendency for
late recurrence, even after complete resection.4,5
Histopathologically, thymomas are primary tumors of
thymic epithelial cells. Thymic carcinoids and thymic carci-
nomas are also tumors of thymic epithelial cells, but thymic
carcinoids are histopathologically and clinically quite differ-
ent from thymomas.6–8 The distinction between thymomas
and thymic carcinomas is not as clear, because thymic car-
cinomas have malignant cytologic features, whereas thymo-
mas are generally considered cytologically benign.9,10 Studies
have demonstrated a markedly decreased survival for thymic
carcinoma compared with thymoma.11–16 Thymic carcinoma
may, therefore, be treated as a distinct pathologic and prog-
nostic entity.
One of the earlier classification systems used for thymo-
mas was based on the predominant cell type—lymphocytic,
epithelial, mixed epithelial, and spindle cell types.17 In 1999, the
World Health Organization (WHO) adopted a pathologic clas-
sification system (Table 1) that takes into account both histologic
and morphologic features. Type A tumors consist of neoplastic
oval or spindle-shaped epithelial cells without atypia or lympho-
cytes (Type AB has foci of lymphocytes). Type B tumors are
characterized by plump epithelial cells, and the subtypes have
increasing proportions of epithelial cells and atypia. Type C
tumors are thymic carcinomas. Detterbeck18 conducted a sys-
tematic review of the literature and reported on the prognostic
value of the WHO classification system. Some of the key
findings from this review concerning the incidence and 10-year
survival of thymoma by histologic types are provided in Table 1.
The tumor, node, metastasis staging system is not partic-
ularly useful for thymomas as most patients do not have nodal
disease or metastases, and, typically, only the extent of the
primary tumor is relevant. The widely used staging classifi-
cation developed by Masaoka et al.19 in 1981 describes
thymomas in terms of the local extension of the tumor. There
are four clinical stages, as shown in Table 2. This staging
system has been shown to correlate well with survival in
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several studies.20–27 The Masaoka staging system is a partic-
ularly useful tool in studies of thymoma, given the rarity and
histopathologic heterogeneity of this tumor. Investigators
have begun to describe the molecular changes that confer
differing degrees of invasiveness and their relationship to the
Masaoka staging system.28–30
Patients with early-stage thymoma are often asymptom-
atic, and the tumor is detected incidentally on a chest x-ray or
computed tomography (CT) scan. Patients with myasthenia
gravis routinely have chest CT scans as part of their workup
because of the high association with thymoma. More ad-
vanced thymoma present with symptoms related to the in-
volvement of local structures. The most common presenting
symptoms for thymomas are dyspnea, chest pain, cough, and
symptoms of myasthenia gravis.31–34 Superior vena cava
syndrome is not an unusual presentation for the patient with
stage III or stage IV thymoma.35,36 In addition to myasthenia
gravis, thymomas are frequently associated with other para-
neoplastic phenomena, and consequently can have quite var-
ied presentations.37–39
The treatment of thymoma may involve surgery, radi-
ation, and chemotherapy. These modalities may be combined;
the combination largely being determined by the stage of the
disease. Although there have been advances in these modal-
ities of care in the last two decades, there is little definitive
evidence to inform best clinical practice. Nonetheless, the
community of clinicians in Ontario expressed the need for
guidance in this area.
This report was developed by the Lung Cancer Disease
Site Group (DSG) through Cancer Care Ontario’s Program in
Evidence-Based Care, which regularly develops practice guide-
lines that are informed by systematic literature reviews and
syntheses of published clinical evidence. For this topic, little
high-quality evidence was available, and a formal consensus-
based methodology was used to supplement the available evi-
dentiary base, thereby allowing the development of reasonable
recommendations for the management of thymoma.
SYSTEMATIC REVIEW
Methods
A systematic review of the literature was conducted on
the treatment of thymoma. Key research questions and clin-
ical outcomes were established a priori by a working group of
clinicians, and a systematic search strategy was developed
and conducted in consultation with a research methodologist.
Precise inclusion and exclusion criteria were established and
applied to the retrieved literature and data were extracted
from the selected publications by a methodologist. The data
were double checked by a second reviewer for accuracy and
summarized in table format.
Literature Search Strategy
The MEDLINE (Ovid) (1996 through June 2006) da-
tabase was searched for relevant published systematic re-
views and primary studies. Search terms included “thymoma”
or “thymic neoplasms.”
Study Selection Criteria
Primary research studies of any design type (e.g., ran-
domized controlled trial [RCT], prospective study, retrospec-
tive chart audit) were included in this systematic review if
they were prospective reports with greater than 10 patients, or
retrospective studies with 100 or more patients; published in
English; reported data on patients with thymoma, and re-
ported data with single or multimodality treatment strategies
involving surgery, chemotherapy, or radiotherapy and clinical
outcomes for treated patients, including response, survival,
and toxicity rates. Studies focusing on myasthenia gravis or
dealing solely with thymic carcinoids or thymic carcinoma,
and trials that pooled survival data of patients with thymoma
and thymic carcinoma or other mediastinal tumors were
excluded. Letters, reviews, and editorials reporting trial data
were also not considered.
Synthesizing the Evidence
The relevant outcome data from the selected studies
were tabulated in tables and arranged by study design and
modality for analysis. Most of the included studies were
retrospective chart audits of patients receiving different treat-
ments for various stages of disease. The few available pro-
spective trials included patients with advanced stage (III/IV)
thymoma treated with chemotherapy and/or radiotherapy and
TABLE 1. World Health Organization (WHO) Pathologic
Classification of Thymoma
WHO
Type Histologic Description
Incidencea
(%)
10-Year
Survivalb (%)
A Medullary thymoma 9 97
AB Mixed thymoma 24 95
B1 Predominantly cortical
thymoma
13 92
B2 Cortical thymoma 24 81
B3 Well-differentiated thymic
carcinoma
15 62
C Thymic carcinoma 15 29
a The incidence of histologic classes of thymoma were reported in 11 retrospective
studies contained in MEDLINE between January 1999 and April 2005; the average
percentages across these studies are reported.
b Ten-year thymoma-specific survival was reported in nine retrospective studies by
histologic class; values are average percentages of these studies.
TABLE 2. Masaoka Clinical Staging of Thymoma
Stage Diagnostic Criteria
I Macro- and microscopically completely encapsulated (tumor
invading into but not through the capsule is included)
II A. Microscopic transcapsular invasion
B. Macroscopic invasion into surrounding fatty tissue or
grossly adherent to but not through mediastinal pleura or
pericardium
III Macroscopic invasion into neighboring organs (i.e., pericardium,
great vessels, or lung)
A. Without invasion of great vessels
B. With invasion of great vessels
IV A. Pleural or pericardial dissemination
B. Lymphogenous or hematogenous metastases
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used a number of different treatment approaches. Because of
this heterogeneity, the data were not appropriate for statistical
pooling.
Consensus-Based Guideline Development Process
Draft recommendations were developed by a working
group comprised members of the Lung DSG. The draft
recommendations were constructed from the evidence con-
tained in the systematic review above and the clinical expe-
rience of members. To obtain consensus on the draft recom-
mendations, clinical experts (i.e., oncologists, pathologists,
and thoracic surgeons) from across Canada who treat thy-
moma participated in a two-round modified Delphi ap-
proach.40,41 The modified Delphi process was chosen because
it provides a formal process for synthesizing expert opinion;
the results are anonymous so the private opinion of each
participant is incorporated; it provides for an explicit method
of aggregating results; and in-person meetings are not re-
quired. The clinical experts were mailed a report consisting of
the systematic review and practice guideline, along with a
questionnaire. In the questionnaire, respondents were asked
to rate their agreement with each recommendation on a
seven-point likert scale, ranging from “strongly agree” to
“strongly disagree.” The draft recommendations were modi-
fied in response to the results of this first consensus round. In
the second consensus round, the original and modified rec-
ommendations, and a questionnaire were mailed to respon-
dents. Respondents were asked to rate their preference for
both the original recommendation and the modified recom-
mendation. If more than 75% of responses were rated as
“strongly agree” or “agree,” the recommendation was con-
sidered to have attained a consensus of “strong agreement.” If
66 to 75% of responses were rated as “strongly agree,” then
the consensus was considered to be “agreement.” If more
than 50% of responses were rated as “strongly disagree” or
“disagree,” then the consensus was considered to be “dis-
agreement.” In all other cases, the consensus was considered
to be “equivocal,” with no clear endorsement or rejection of
the recommendation. The complete methods of the consensus
process are published elsewhere. The resulting clinical prac-
tice guideline was reviewed and approved by the Program in
Evidence-Based Care Report Approval Panel.
RESULTS
Literature Search Results
The literature search retrieved 215 unique journal pub-
lications from MEDLINE. After filtering the abstracts ac-
cording to the selection criteria, 13 studies met the inclusion
criteria, and these publications were retrieved for data extrac-
tion. No systematic reviews or evidence-based practice guide-
lines were identified. Five studies of surgery as primary treat-
ment were eligible for inclusion and included a single RCT,
three retrospective case reports (with sample sizes ranging
from 140 to 370), and one survey. Nine prospective studies of
chemotherapy (single modality n  5, multimodality n  3)
or radiotherapy (n  1) were eligible for inclusion and had
sample sizes ranging from 16 to 38 patients.
Outcomes
Surgery as Primary Treatment in Multimodality
Strategies for Thymoma
One small RCT (n  29) involving completely resected
stage I thymoma randomized patients to surgery alone (n 13)
or to surgery followed by adjuvant radiation (n  16). All
patients underwent resection through a median sternotomy. Fol-
low-up ranged from 1 to 15 years. The authors found no
difference in 5 and 10-year survival between the two groups and
no recurrence or metastases in either group.42 The trial had very
low statistical power because of its small size; a priori power
calculations were not reported by the trial authors.
Three retrospective chart audits3,26,43 and a survey44
with greater than 100 patients reported outcomes associated
TABLE 3. Retrospective Evidence of Surgery as Primary
Treatment in Multimodality Strategies for Thymomaa
Trial N
Resections (%)
Overall
Survival
(%)
Complete Incomplete 5 yr 10 yr
Retrospective chart audits
Okumura et al.26
Total 194 87 11
I 78 NR NR 99
II 94 94
III 56 88
IVA 10 30
IVB 6 0
Murakawa et al.43
Total 140
I 64 91 80
II 32 97 92
III 28 68 54
IV 16 69 60
Regnard et al.3
Total 370 70 8 67
I 135 NR NR
II 70
III 83
IV 19
Survey
Kondo and Monden44
Total 1093 88 5
I 522 100 0 100
II 247 100 0 95
III 204 63 16 89
IVA 73 71
IVB 35 53
a Multimodality therapies included postoperative adjuvant chemotherapy and ra-
diotherapy, varying by stage and study as detailed below.
Okumara et al., 1999—postoperative radiation to mediastinum: all patients 1957–
1985; limited to patients with invasive thymoma including stages II, III, IV 1986–1996.
Chemotherapy: all stage IV and stage III where resection is incomplete.
Murakawa et al., 2000—postoperative irradiation for stages II, III, and IV.
Regnard et al., 1996—postoperative radiotherapy for invasive thymoma: 13% of
stage I, 78% of stage II, and 83% of stage III. For stage IV, 90% had postoperative
radiotherapy and/or chemotherapy.
N, number of patients; NR, not reported.
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with primary surgical resection of thymoma as part of mul-
timodality treatment strategies, including adjuvant chemo-
therapy and radiotherapy. A large survey of 185 institutes
certified by the Japanese Association for Chest Surgery was
reported by Kondo et al.44 in 2003. Records of 1093 thymoma
patients were compiled, and these data were reported by stage
and treatment modality.
The stage-specific survival, operative morbidity and mor-
tality, and overall survival for surgical resection from the four
studies are shown in Table 3. The studies involve a wide range
of treatment approaches, making it difficult to correlate specific
multimodality treatment regimens with survival. Five-year over-
all survival rates were reported by stage. For stage I, 5-year
survival ranged from 89 to 100%; for stage II 71 to 97%; for
stage III 68 to 89%, and for stage IV, 47 to 69%. Overall,
survival rates were quite high for early-stage disease but fol-
lowed a decreasing survival trend for more advanced disease.
Despite reduced survival in advanced disease, maximal debulk-
ing surgery seems beneficial, facilitating radiotherapy and
thereby improving survival.45 Ten-year survival rates were
somewhat lower and exhibited a similar trend by stage.
Chemotherapy and Radiotherapy in Single and
Multimodality Treatment for Advanced Thymoma
Data from the prospective studies of chemotherapy or
radiotherapy in the management of advanced thymoma were
compiled. Advanced thymoma, as described in these trials,
refers to later stage disease, typically stages III and IVA or B.
Trials included patients with disease characterized as being
locally advanced, invasive, malignant, recurrent, and unre-
sectable.
Neoadjuvant Chemoradiotherapy in Multimodality
Treatment
Limited data on the outcomes associated with neoad-
juvant chemoradiotherapy in advanced thymoma are avail-
able (Table 4). In most studies, sample sizes were too small
to permit meaningful statistical comparisons. The three avail-
able prospective studies included a total of 61 patients and
ranged in sample size from 16 to 23 patients.46–48 PAC
(cyclophosphamide, doxorubicin, cisplatin) was the most
commonly used chemotherapy regimen, although one trial
investigated ADOC (cisplatin doxorubicin, vincristine, and
cyclophosphamide). The median age of patients ranged from
47 to 55 years. Resections were performed after chemother-
apy, with varying degrees of success. Radiotherapy was
sequential to chemotherapy in all trials. Follow-up ranged
from 14 to 50 months.
Overall response rates ranged from 70 to 81%; complete
responses were much less frequent and ranged from 6 to 22%.
Five-year survival varied considerably and ranged from 31 to
95%; progression-free survival was substantially lower and
ranged from 31 to 77%.
Chemotherapy as a Single Treatment Modality
Limited data on outcomes associated with chemother-
apy as the primary therapy in advanced thymoma are avail-
able (Table 5). In most studies, there were too few patients
enrolled to permit meaningful statistical comparisons. The
five available prospective studies included a total of 111
patients, and ranged in sample size from 13 to 38 pa-
tients.49–53 Chemotherapy regimens varied among the trials,
and included octreotide, cisplatin, etoposide, ifosfamide, and
others. In one trial,50 all patients enrolled were refractory to at
least one prior chemotherapy regimen.
Overall response rates ranged from 32 to 56%, but
complete responses were less frequent and ranged from 0 to
38%. Overall 2-year survival varied considerably and ranged
from 30 to 79%; progression-free survival was reported less
frequently but was generally lower, with rates ranging from
13 to 56%.
Radiotherapy as a Single Treatment Modality
Only one prospective trial (n  25) of single modality
radiotherapy in advanced thymoma was retrieved54 (Table 6).
All patients had malignant invasive stage III thymoma, and
the authors did not report any other therapy being prescribed.
The mean radiation dose was 46.36 Gy (range, 32.4–58 Gy).
Fraction sizes ranged from 1.8 to 2.0 Gy per day, 5 days per
week. Five-year overall survival and progression-free sur-
TABLE 4. Prospective Trials of Neoadjuvant Chemoradiotherapy in Multimodality Treatment of Advanced Thymoma (Stages III/IV)
Trial
N
(%III, %IV)a Agentsb
Surgery
R0, R
RT Dose
Gy
FU
Median
Response (%)
Survival 5-yr,
Median
CR ORR OS DFS PFS
Kim et al.46 22 (50, 50) PAC  PDN 16, 5 50–60 50 14 76 95% NR 77%, NR
Berruti et al.47 16 (63, 38) ADOC 9, NR 45c NR 6 81 31%, 48 31%, 33 NR
Loehrer et al.48 23 (96, 4) PAC 0, 4 54d 14, 125e 22 70 53%, 93 54%, 93f
a Percentage values indicate proportion of sample with stages III and IV disease.
b Dosage amounts and schedules varied by study.
c Only 13 of 16 patients received radiotherapy.
d Radiation provided concurrent with chemotherapy.
e Minimum follow-up was 14 mo for ECOG patients and 125 mo for SECSG/SWOG patients.
f Five-year failure-free rate, median time-to-treatment failure.
ADOC, cisplatin  doxorubicin, vincristine, cyclophosphamide; CR, number of patients achieving a complete response; dose, refers to the total radiation dose given patients;
D/PFS, disease or progression-free survival, percentage values indicate proportion alive without disease progression at 5 yr; numerical values indicate median progression-free
survival time in months; ECOG, Eastern Cooperative Oncology Group; FU, follow-up in months; Gy, Gray; N, number of evaluable patients; NR, not reported; ORR, CR plus number
of patients achieving a partial response; OS, overall survival rate, percentage values indicate proportion alive at follow-up period; numerical values indicate median survival time
in months; PAC, cyclophosphamide, doxorubicin, cisplatin; PDN, prednisone; R0, complete resection; R, residual; RT, radiotherapy; SECSG/SWOG, Southeastern Cancer Study
Group/Southwest Oncology Group.
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vival were 72 and 81%, respectively, and recurrence at 5
years was 15%.
DISCUSSION
Over the past 12 years, the Lung DSG has produced 25
evidence-based guidelines on various aspects of lung can-
cer.55 The Lung DSG has always placed great emphasis on
the results from published RCTs (level 1 evidence) in making
its clinical recommendations. This systematic review on thy-
moma management revealed very little high-quality evidence.
The rarity of the disease makes it difficult to conduct random-
ized trials with adequate sample sizes to detect clinically signif-
icant differences in outcome. Because of the interest expressed
by clinicians for guidance in this area, the Lung DSG under-
took to produce a guideline despite the paucity of high-
quality evidence on this topic. For the first time, the Lung
DSG used a different approach and employed a formal
consensus method. A description of the consensus methods
used (a two-round modified Delphi process), the results
obtained, and a discussion of the consensus process are
presented in a separate manuscript.
Surrogate end points should be used cautiously. The three
prospective trials of neoadjuvant chemoradiotherapy in multi-
modality treatment of advanced thymoma considered tumor
response as an outcome. Complete response in these trials was
low, but overall survival was relatively high demonstrating a
lack of a consistent relationship with survival. Response rates are
typically lower in disseminated disease versus locally advanced
disease.56 One trial,48 which included patients with limited stage
disease only, did show a higher response rate.
Although advances in the last two decades have occurred
in the treatment of thymoma, there is little definitive evidence to
inform best clinical practice. Given the rare nature of these
tumors and the multiple acceptable approaches to treatment, it
was difficult for the Lung DSG to make definitive recommen-
dations. The current data do not adequately address certain
controversial topics, which include: the role of adjuvant treat-
ment in stage II disease; the choice, timing, and sequencing of
combined modality therapy (i.e., surgery, radiotherapy, and
chemotherapy) in stage III disease; identifying for whom sur-
gery is appropriate, and whether debulking surgery is appropri-
ate in unresectable or disseminated disease as there is limited
evidence to refute or support it; and determining the best treat-
ment approach to recurrent disease. At present, there is individ-
ual and institutional variation in the timing and sequencing of
treatment and what extent of disease is regarded as being
resectable. Adjuvant radiation in the treatment of stage II disease
remains controversial and some experts may feel that modern
evidence may not support the use of radiation in completely
resected disease. It is because of such controversies the authors
used a consensus approach, and the recommendations are thus
those of the majority opinion.
Practice Guideline
The following 40 recommendations for the manage-
ment of thymoma by surgery, radiotherapy, and systemic
therapy were developed through a combination of systematic
review of the medical literature and a formal consensus
process and are based on the Masaoka staging system.
Consensus Recommendations for the
Management of Thymoma
Stage I
Surgery
1. Complete surgical resection of the entire thymus
gland, including all mediastinal tissues anterior to the
TABLE 5. Prospective Trials of Primary Chemotherapy in Single Modality Treatment of Advanced
Thymoma (Stages III/IV)
Trial
N
(%III, %IV)a Agentsb Agec FU
Response (%)
Survival,
2 yr (%)
CR ORR OS PFS
Loehrer et al.49 38 (5, 89) O, O  PDN 51 50 5 53 76 13
Palmieri et al.50 16d (25, 69) O or L, PDN 51 43 6d 37d 30 25
Loehrer et al.51 28 (21, 78) P  E  I 55 43 0 32 70 NR
Highley et al.52 13 (27, 73) I 48 NR 38 46 73 NR
Giaccone et al.53 16 (NR) P  E 45 84 31 56 79 56
a Percentage values indicate proportion of sample with stages III and IVA and/or IVB disease, where reported.
b Dosage amounts and schedules varied by study.
c Median age of patients at start of therapy.
d This study included only previously treated patients refractory to chemotherapy, nine of which had received prior surgery.
CR, number of patients achieving a complete response; E, etoposide; FU, median duration of follow-up in months; I, ifosfamide; L, lanreotide;
N, number of evaluable patients; NR, not reported; O, octreotide; P, cisplatin; PDN, prednisone; PFS, progression-free survival, percentage values
indicate proportion alive without disease progression at 2 yr, numerical values indicate median progression-free survival time in months; ORR, CR
plus number of patients achieving a partial response; OS, overall survival rate, percentage values indicate proportion alive at 2 yr.
TABLE 6. Prospective Trials of Primary Radiotherapy
Treatment of Advanced Thymoma (Stage III)
Trial N Dose
Survival (%)
15% at 5 yrOS 5 yr DFS 5 yr
Sur et al.54 25 46.36 Gy (mean) 72 81 15% at 5 yr
DFS, disease-free survival rate; Gy, gray; N, number of evaluable patients; OS,
overall survival rate.
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pericardium, aorta, and superior vena cava from
phrenic nerve to phrenic nerve laterally and from the
diaphragm inferiorly to the level of the thyroid gland
superiorly, including the upper poles of the thymus, is
recommended as the standard of care.
2. For resection of thymoma, an open median sternotomy
surgical approach is recommended.
3. Minimally invasive approaches (e.g., video-assisted
thoracic surgery) are not considered the standard of
care and are not recommended at this time.
Radiotherapy
4. Neither postoperative nor neoadjuvant radiotherapy is
recommended for stage I disease.
Systemic Therapy
5. Neither postoperative nor neoadjuvant systemic ther-
apy is recommended for stage I disease.
Medically Inoperable Stage I Disease
6. Chemoradiation or radiation alone should be consid-
ered for patients who are medically unfit for surgery.
Stage II
Surgery
7. Complete surgical resection (as outlined for stage I) is
the usual practice and is the recommended standard of
care.
8. For resection of thymoma, an open median sternotomy
surgical approach is recommended.
9. Minimally invasive approaches (e.g., video-assisted
thoracic surgery) are not considered the standard of
care and are not recommended at this time.
Radiotherapy
10. Routine adjuvant radiation is currently not recom-
mended for stage IIA disease. Radiation should be
considered in patients with high risk for local recur-
rence. These risk factors include: invasion through the
capsule (stage IIB), close surgical margins, WHO
grade B type, and tumor adherent to pericardium.
11. Radiotherapy has risks for acute and long-term toxic-
ity, notably a risk for the development of secondary
malignancies57 and coronary artery disease.58 Possible
risks and benefits need to be discussed with patients,
particularly in younger individuals.
Systemic Therapy
12. Neither postoperative nor neoadjuvant systemic ther-
apy is recommended for stage II disease.
Medically Inoperable Stage II Disease
13. Chemoradiation or radiation alone should be consid-
ered for patients who are medically unfit for surgery.
Stage III
14. Patients presenting with locally advanced or metastatic
disease should be carefully evaluated for multimodal-
ity therapy that includes neoadjuvant chemotherapy,
surgical resection, or adjuvant postoperative chemora-
diotherapy.
Resectable or Potentially Resectable Stage III Disease
Surgery
15. Surgery should be considered for stage IIIA disease
either initially or after neoadjuvant therapy, with the
aim being complete removal of the tumor with wide
surgical margins. Patients with stage IIIB disease should
be assessed for surgery after neoadjuvant chemoradio-
therapy.
16. If at thoracotomy complete resection is not possible,
maximal debulking (with appropriate vascular recon-
struction) should be undertaken. Clips should be
placed to mark residual tumor to facilitate adjuvant
radiation. Neoadjuvant chemoradiation should be con-
sidered before surgery if preoperative assessment in-
dicates that complete resection may not be feasible.
17. Bilateral phrenic nerve resection is not recommended
because of the severe respiratory morbidity it causes.
Neoadjuvant Radiotherapy and Systemic Therapy
18. Neoadjuvant chemoradiotherapy is commonly used in
this setting.
• The data supporting this standard are not yet estab-
lished.
19. The optimal neoadjuvant therapy regimen for minimiz-
ing operative morbidity and mortality, and maximizing
resectability and survival rates is not yet established.
• Cisplatin-based combination chemotherapy regi-
mens are recommended as reasonable options. Most
of the clinical experience with combined modality
therapy is with cisplatin and anthracycline combi-
nations.
20. The optimal sequencing of radiotherapy and chemo-
therapy is not yet established.
• If treatment volumes are small, concurrent chemo-
radiotherapy is recommended as a reasonable op-
tion.
If the initial tumor volume is considered to be too bulky,
sequential therapy, with chemotherapy followed by radia-
tion therapy, is recommended as a reasonable option.
Resection may be performed before radiotherapy.
21. The diagnosis of thymoma should be established by
either a CT-guided core-needle biopsy or an open surgi-
cal biopsy before considering neoadjuvant therapy.
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Adjuvant Radiotherapy and Systemic Therapy
22. Adjuvant radiotherapy is commonly used in this set-
ting and is recommended. Adjuvant chemotherapy
may be a consideration; however, there is not enough
data to routinely recommend adjuvant chemotherapy
after complete resection.
Unresectable Stage III Disease
23. Where surgery is inappropriate, chemotherapy concur-
rent with, or sequential to, radiation therapy is recom-
mended.
24. The definition of unresectable disease is debated, and
may vary with surgical expertise, but is generally
defined as extensive tumor involving middle medias-
tinal organs such as the trachea, great arteries, and/or
heart that has not responded to cisplatin-based combi-
nation chemotherapy. The role of debulking surgery in
such situations is controversial.
Stage IVA
25. The recommendations established for stage III disease
are applicable to stage IVA disease. The following are
notable modifications or exceptions to this:
Resectable or Potentially Resectable Stage IVA Disease
Surgery
26. Surgery should be considered either initially or after
neoadjuvant therapy, with the aim being complete
resection of the tumor with wide surgical margins.
Surgery is recommended only if pleural and pericar-
dial metastases can be resected.
Neoadjuvant Radiotherapy and Systemic Therapy
27. Neoadjuvant chemoradiotherapy is an option in this
setting.
28. Cisplatin-based combination chemotherapy regimens
are reasonable options.
Adjuvant Radiotherapy and Systemic Therapy
29. Adjuvant chemoradiotherapy is an option.
Unresectable Stage IVA Disease
30. Where surgery is not feasible because of very ex-
tensive or technically unresectable pleural or peri-
cardial metastases, chemotherapy is commonly pro-
vided. Chemotherapy concurrent with, or sequential
to, radiation therapy is also an option. Cisplatin plus
anthracycline-containing regimens are the most
commonly used first-line chemotherapy. Patients
may often respond to multiple sequential therapies
with single agents after progression on first-line
therapy.
31. In stage IVA, unresectable disease may include exten-
sive bilateral and/or pleural-based disease and pericar-
dial metastases.
Stage IVB
32. These types of thymoma are extremely rare, and ge-
neric recommendations are not possible.
Surgery
33. Not applicable.
Radiotherapy
34. Radiotherapy may be appropriate, particularly for life-
threatening situations.
Systemic Therapy
35. Cisplatin-based combination chemotherapy is an ap-
propriate option. Cisplatin plus anthracycline-contain-
ing regimens are the most commonly used first-line
chemotherapy. Patients may often respond to multiple
sequential therapies with single agents after progres-
sion on first-line therapy.
36. Octreotide, alone, or in combination with a corticoste-
roid may be a reasonable option for recurrent cases.
Recurrent Disease
Surgery
37. Surgical resection should be considered in patients
with a localized recurrence after apparently successful
initial therapy. In some patients with stage IV disease,
the resection of isolated pleural metastases is an ap-
propriate initial approach. For cases with multiple
pleural metastases, chemotherapy, with or without
subsequent surgery, is often appropriate.
Radiotherapy
38. Radiotherapy may be appropriate either alone or in
combination with chemotherapy.
Systemic Therapy
39. Cisplatin-based chemotherapy may be an appropriate
therapy as part of combined chemoradiotherapy.
40. Octreotide, alone, or in combination with a corticoste-
roid, may be a reasonable option.
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